Correspondence 0001104659-23-066352 from YS Biopharma Co., Ltd. (LSB, LSBPW) (CIK 0001946399) (LSBCF)
YS Biopharma Co., Ltd. (LSB, LSBPW) (CIK 0001946399)
Date: May 31, 2023 · CIK: 0001946399 · Accession: 0001104659-23-066352
AI Filing Summary & Sentiment
File numbers found in text: 333-271221
Letter
Via EDGAR Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: YS Biopharma Co., Ltd. (CIK No. 0001946399) Registration Statement on Form F-1 (Registration No. 333-271221)
Dear Mr. Jimmy McNamara and Mr. Jason Drory,
Pursuant to Rule 461 of Regulation C (“Rule 461”) promulgated under the Securities Act of 1933, as amended, YS Biopharma Co., Ltd. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form F-1, as amended (the “F-1 Registration Statement”), be accelerated to, and that the F-1 Registration Statement become effective at, 10:00 a.m., Eastern Time on June 5, 2023 or as soon thereafter as practicable.
If there is any change in the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration of the effectiveness of the F-1 Registration Statement in accordance with Rule 461. Such request may be made by an executive officer of the Company or by any attorney from the Company’s U.S. counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation.
[Signature page follows]
Very truly yours,
YS Biopharma Co., Ltd.
Show Raw Text
CORRESP
1
filename1.htm
May 31, 2023
Via EDGAR
Mr. Jimmy McNamara
Mr. Jason Drory
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: YS Biopharma Co., Ltd. (CIK No. 0001946399)
Registration Statement on Form F-1 (Registration
No. 333-271221)
Dear Mr. Jimmy McNamara and Mr. Jason
Drory,
Pursuant to Rule 461 of Regulation C (“Rule 461”)
promulgated under the Securities Act of 1933, as amended, YS Biopharma Co., Ltd. (the “Company”) hereby requests
that the effectiveness of the above-referenced registration statement on Form F-1, as amended (the “F-1 Registration Statement”),
be accelerated to, and that the F-1 Registration Statement become effective at, 10:00 a.m., Eastern Time on June 5, 2023 or as soon
thereafter as practicable.
If there is any change in the acceleration request
set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration
of the effectiveness of the F-1 Registration Statement in accordance with Rule 461. Such request may be made by an executive officer
of the Company or by any attorney from the Company’s U.S. counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation.
[Signature page follows]
Very truly yours,
YS Biopharma Co., Ltd.
By:
/s/ Yi Zhang
Name:
Yi Zhang
Title:
Director and Chairperson